Thermo Fisher Scientific

TMO

Market cap $199B

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has introduced the Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer, designed for fast and scalable sample analysis. In conjunction with two new arrays – the Applied Biosystems Axiom™ PharmacoPro™ Array and the Applied Biosystems Axiom PangenomePro Array – the analyzer combines four key genotyping processes into a single, integrated device, enabling researchers to cover the widest range of p.

Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Franklin Street Advisors reported purchasing 87,872 shares of Thermo Fisher Scientific in the quarter ended September 30, 2025. This was an estimated $40.90 million trade based on the average price for the quarter, per its October 9, 2025, SEC filing.

On October 10, 2025, wealth management company Douglas Lane & Associates disclosed a purchase of Thermo Fisher Scientific valued at approximately $7.79 million, based on the average price for Q3 2025.

WEST HILLS, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has introduced a new laboratory developed test for post-transplant biopsy assessment designed to improve the detection of lung transplant rejection and injury, delivering quantifiable results that may increase diagnostic confidence and guide timely treatment. Due to the significant risk of rejection, lung transplant recipients often require routine biopsies to monitor the health of their new lung.

TMO joins AstraZeneca's BioVentureHub to boost R&D, innovation and life science access.

The Top 15 High-Growth Dividend Stock list for October 2025 targets a 12% long-term return, despite underperforming SPY and VIG in September. These 15 stocks offer a 1.4% average yield and have grown dividends at 19.1% annually over five years, with many trading at significant discounts. Recent changes include six new additions, with expected long-term CAGRs near 20% based on dividend yield theory and valuation metrics.

WILMINGTON, N.C.--(BUSINESS WIRE)--Thermo Fisher Scientific announces R&D partnership with AstraZeneca BioVentureHub.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2025 before the market opens on Wednesday, October 22, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. Th.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $2.5 billion aggregate principal amount (the “Offering”) of the following notes: $500 million aggregate principal amount of its 4.200% senior notes due 2031 (the “2031 notes”) at the issue price of 99.874% of their principal amount; $750 million aggregate principal amount of its 4.473% senior notes due 2032 (the “2032 notes”) at the issue price of 100.00.